Maplight Therapeutics (NASDAQ:MPLT) Insider Erin Pennock Foff Sells 15,652 Shares

Maplight Therapeutics, Inc. (NASDAQ:MPLT) insider Erin Pennock Foff sold 15,652 shares of the stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $27.96, for a total value of $437,629.92. Following the transaction, the insider owned 385,125 shares of the company’s stock, valued at approximately $10,768,095. This trade represents a 3.91% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Erin Pennock Foff also recently made the following trade(s):

• On Wednesday, May 6th, Erin Pennock Foff sold 24,052 shares of Maplight Therapeutics stock. The shares were sold at an average price of $28.76, for a total value of $691,735.52.
• On Tuesday, May 5th, Erin Pennock Foff sold 10,576 shares of Maplight Therapeutics stock. The shares were sold at an average price of $28.20, for a total value of $298,243.20.

Maplight Therapeutics Stock Up 4.0%

Shares of NASDAQ MPLT traded up $1.12 during mid-day trading on Wednesday, hitting $29.04. The company had a trading volume of 267,979 shares, compared to its average volume of 342,018. The company has a market cap of $1.24 billion and a P/E ratio of -0.73. The company has a 50-day moving average price of $22.60. Maplight Therapeutics, Inc. has a one year low of $12.24 and a one year high of $33.28.

Maplight Therapeutics (NASDAQ:MPLT) last posted its quarterly earnings results on Thursday, March 26th. The company reported ($2.47) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.05) by ($1.42). On average, sell-side analysts forecast that Maplight Therapeutics, Inc. will post -3.96 earnings per share for the current year.

Maplight Therapeutics News Summary

Here are the key news stories impacting Maplight Therapeutics this week:

• Positive Sentiment: Needham reaffirmed its “Buy” rating on MPLT, signaling continued analyst conviction that the shares have upside. Needham Reaffirms Buy
• Positive Sentiment: HC Wainwright initiated/updated coverage with a “Buy” rating and a $45 price target (roughly mid‑50% upside from recent levels), which can attract buyers and support the rally. Many outlets reported the new coverage and target. HC Wainwright Coverage & Target
• Neutral Sentiment: Morningstar and market quote pages show current trading context (price, volume, 50‑day moving average) that traders use to gauge technical support/resistance. Use these pages for up‑to‑date quotes. Morningstar Quote
• Negative Sentiment: HC Wainwright’s detailed forecasts also project larger net losses over 2026–2027 (FY2026 EPS ~ -$4.34; FY2027 EPS ~ -$5.25) and quarterly losses through 2027 — data that underscores continued cash‑burn and execution risk for a clinical‑stage biotech. This raises downside risk if clinical or financing progress stalls. Analyst Estimates
• Negative Sentiment: Recent reported results included a sizable Q1 EPS miss (reported -$2.47 vs. consensus -$1.05), which remains a reminder of earnings volatility and could pressure sentiment if follow‑up data or guidance are weak. Recent Earnings Miss

Wall Street Analysts Forecast Growth

MPLT has been the topic of a number of research reports. Weiss Ratings started coverage on Maplight Therapeutics in a report on Thursday, January 22nd. They issued a “sell (e)” rating on the stock. TD Cowen began coverage on shares of Maplight Therapeutics in a research report on Tuesday, April 7th. They issued a “buy” rating for the company. HC Wainwright assumed coverage on shares of Maplight Therapeutics in a research report on Monday. They set a “buy” rating and a $45.00 price objective for the company. Needham & Company LLC initiated coverage on shares of Maplight Therapeutics in a research report on Wednesday, April 8th. They issued a “buy” rating and a $37.00 price target for the company. Finally, Canaccord Genuity Group assumed coverage on shares of Maplight Therapeutics in a research report on Thursday, March 19th. They set a “buy” rating and a $35.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $34.43.

Hedge Funds Weigh In On Maplight Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. Strs Ohio acquired a new position in Maplight Therapeutics during the fourth quarter worth about $53,000. Police & Firemen s Retirement System of New Jersey acquired a new position in Maplight Therapeutics during the fourth quarter worth about $70,000. New York State Common Retirement Fund acquired a new position in Maplight Therapeutics during the fourth quarter worth about $93,000. MetLife Investment Management LLC acquired a new position in Maplight Therapeutics during the fourth quarter worth about $172,000. Finally, Walleye Capital LLC acquired a new position in Maplight Therapeutics in the 4th quarter valued at about $205,000.

Maplight Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.